readthroughSign in
CompanyGLPGFLKFTNasdaq, OTC2800 Mechelen

Lakefront Biotherapeutics NV

Lakefront Biotherapeutics develops gamgertamig, a BCMAxCD3 T-cell engager in clinical development for autoimmune diseases.

6-KNov 16Latest SEC filing
Nov 12Latest story